• 文献标题:   Dual Drugs Anticancer Nanoformulation using Graphene Oxide-PEG as Nanocarrier for Protocatechuic Acid and Chlorogenic Acid
  • 文献类型:   Article
  • 作  者:   BULLO S, BUSKARAN K, BABY R, DORNIANI D, FAKURAZI S, HUSSEIN MZ
  • 作者关键词:   anticancer, chlorogenic acid ca, drug delivery, graphene oxide, nanobiomaterial, polyethylene glycol peg protocatechuic acid pca
  • 出版物名称:   PHARMACEUTICAL RESEARCH
  • ISSN:   0724-8741 EI 1573-904X
  • 通讯作者地址:   Univ Putra Malaysia
  • 被引频次:   10
  • DOI:   10.1007/s11095-019-2621-8
  • 出版年:   2019

▎ 摘  要

BackgroundThe chemotherapy of cancer has been complicated by poor bioavailability, adverse side effects, high dose requirement, drug resistance and low therapeutic indices. Cancer cells have different ways to inhibit the chemotherapeutic drugs, use of dual/multiple anticancer agents may be achieve better therapeutic effects in particular for drug resistant tumors. Designing a biocompatible delivery system, dual or multiple drugs could addressing these chemotherapy drawbacks and it is the focus of many current biomedical research.MethodsIn the present study, graphene oxide-polyethylene glycol (GOPEG) nanocarrier is designed and loaded with two anticancer drugs; Protocatechuic acid (PCA) and Chlorogenic acid (CA). The designed anticancer nanocomposite was further coated with folic acid to target the cancer cells, as their surface membranes are overexpressed with folate receptors.ResultsThe particle size distribution of the designed nanocomposite was found to be narrow, 9-40nm. The release profiles of the loaded drugs; PCA and CA was conducted in human body simulated PBS solutions of pH7.4 (blood pH) and pH4.8 (intracellular lysosomal pH). Anticancer properties were evaluated against cancerous cells i.e. liver cancer, HEPG2 and human colon cancer, HT-29 cells. The cytocompatbility was assessed on normal 3T3 fibroblasts cells.ConclusionThe size of the final designed anticancer nanocomposite formulation, GOPEG-PCACA-FA was found to be distributed at 9-40 nm with a median of 8 nm. The in vitro release of the drugs PCA and CA was found to be of sustained manner which took more than 100h for the release. Furthermore, the designed formulation was biocompatible with normal 3T3 cells and showed strong anticancer activity against liver and colon cancer cells.